Active-targeted nanotherapy strategies for prostate cancer

Current Cancer Drug Targets

Volumn 11, Issue 8, 2011, Pages 954-965

  Katsogiannou, M ^a,b   Peng, L ^c   Catapano, C V ^d   Rocchi, P ^a,b  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITÉ   (France)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Active targeting; Castration resistant prostate cancer; Nanotherapeutics; Prostate cancer; Receptor overexpression; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; DENDRIMER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; LIGAND; LIPOSOME; MEMBRANE ANTIGEN; NANOPARTICLE; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SGN 15; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOCYTOSIS; HALF LIFE TIME; HUMAN; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PROSTATE CANCER; SURFACE PROPERTY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOSTRUCTURES; PROSTATIC NEOPLASMS;

EID: 80052835189     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911797264770     Document Type: Article

References (179)

1. American Cancer Society: prostate cancer statistics. http://www.cancer.org.
2. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60 (5), 277-300.
3. Ferlay, J. S. H.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr.
4. Sharifi, N.; Gulley, J. L.; Dahut, W. L. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294 (2), 238-244.
5. Eisenberger, M. A.; Blumenstein, B. A.; Crawford, E. D.; Miller, G.; McLeod, D. G.; Loehrer, P. J.; Wilding, G.; Sears, K.; Culkin, D. J.; Thompson, I. M., Jr.; Bueschen, A. J.; Lowe, B. A. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 1998, 339 (15), 1036-1042.
6. Crawford, E. D.; Eisenberger, M. A.; McLeod, D. G.; Spaulding, J. T.; Benson, R.; Dorr, F. A.; Blumenstein, B. A.; Davis, M. A.; Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 1989, 321 (7), 419-424.
7. Eisenberger, M. A.; Walsh, P. C., Early androgen deprivation for prostate cancer? N. Engl. J. Med. 1999, 341 (24), 1837-1838.
8. Stavridi, F.; Karapanagiotou, E. M.; Syrigos, K. N. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat. Rev. 2010, 36 (2), 122-130.
9. So, A.; Gleave, M.; Hurtado-Col, A.; Nelson, C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol. 2005, 23 (1), 1-9.
10. Scher, H. I.; Sawyers, C. L. Biology of progressive, castration resistant prostate cancer: directed therapies targeting the androgen receptor signaling axis. J. Clin. Oncol. 2005, 23 (32), 8253-8261.
11. Lassi, K.; Dawson, N. A. Update on castrate-resistant prostate cancer: 2010. Curr. Opin. Oncol. 2010, 22 (3), 263-267.
12. Di Lorenzo, G.; Buonerba, C.; Autorino, R.; De Placido, S.; Sternberg, C. N. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010, 70 (8), 983-1000.
13. DeMarzo, A. M.; Nelson, W. G.; Isaacs, W. B.; Epstein, J. I. Pathological and molecular aspects of prostate cancer. Lancet 2003, 361 (9361), 955-964.
14. Kumar-Sinha, C.; Tomlins, S. A.; Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8 (7), 497-511.
15. Shen, M. M.; Abate-Shen, C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24 (18), 1967-2000.
16. Shah, R. B.; Mehra, R.; Chinnaiyan, A. M.; Shen, R.; Ghosh, D.; Zhou, M.; Macvicar, G. R.; Varambally, S.; Harwood, J.; Bismar, T. A.; Kim, R.; Rubin, M. A.; Pienta, K. J. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004, 64 (24), 9209-9216.
17. Lapointe, J.; Li, C.; Higgins, J. P.; van de Rijn, M.; Bair, E.; Montgomery, K.; Ferrari, M.; Egevad, L.; Rayford, W.; Bergerheim, U.; Ekman, P.; DeMarzo, A. M.; Tibshirani, R.; Botstein, D.; Brown, P. O.; Brooks, J. D.; Pollack, J. R. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (3), 811-816.
18. Bianchini, D.; Zivi, A.; Sandhu, S.; de Bono, J. S. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Ann. Oncol. 2010, 21 Suppl 7, 743-755.
19. Lammers, T.; Hennink, W. E.; Storm, G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 2008, 99 (3), 392-397.
20. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7 (9), 771-782.
21. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2 (10), 750-763.
22. Sahoo, S. K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today 2003, 8 (24), 1112-1120.
23. Mozafari, M. R.; Pardakhty, A.; Azarmi, S.; Jazayeri, J. A.; Nokhodchi, A.; Omri, A. Role of nanocarrier systems in cancer nanotherapy. J. Liposome Res. 2009, 19 (4), 310-321.
24. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2 (12), 751-760.
25. Farokhzad, O. C. Nanotechnology for drug delivery: the perfect partnership. Expert Opin. Drug Deliv. 2008, 5 (9), 927-929.
26. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2 (5), 347-60.
27. Ahmad, M. Z.; Akhter, S.; Jain, G. K.; Rahman, M.; Pathan, S. A.; Ahmad, F. J.; Khar, R. K. Metallic nanoparticles: technology overview & drug delivery applications in oncology. Expert Opin. Drug Deliv. 2010, 7 (8), 927-942.
28. Sawant, R. R.; Torchilin, V. P. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol. Membr. Biol. 2010, 27 (7), 232-246.
29. Thomas, M.; Klibanov, A. M. Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (16), 9138-9143.
30. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5 (4), 505-515.
31. Bartlett, D. W.; Davis, M. E. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 2007, 18 (2), 456-468.
32. Song, E.; Zhu, P.; Lee, S. K.; Chowdhury, D.; Kussman, S.; Dykxhoorn, D. M.; Feng, Y.; Palliser, D.; Weiner, D. B.; Shankar, P.; Marasco, W. A.; Lieberman, J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005, 23 (6), 709-717.
33. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D. A.; Torchilin, V. P.; Jain, R. K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55 (17), 3752-3756.
34. Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (8), 4607-4612.
35. Venturoli, D.; Rippe, B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am. J. Physiol. Renal. Physiol. 2005, 288 (4), F605-F613.
36. Li, S. D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5 (4), 496-504.
37. Heidel, J. D.; Davis, M. E. Clinical developments in nanotechnology for cancer therapy. Pharm. Res. 2010.
38. Choi, H. S.; Liu, W.; Liu, F.; Nasr, K.; Misra, P.; Bawendi, M. G.; Frangioni, J. V. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol. 2010, 5 (1), 42-47.
39. Zamboni, W. C. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin. Cancer Res. 2005, 11 (23), 8230-8234.
40. Bader, A. G.; Brown, D.; Winkler, M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70 (18), 7027-7030.
41. Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8 (2), 129-138.
42. Li, S. D.; Chono, S.; Huang, L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J. Control Release 2008, 126 (1), 77-84.
43. Liu, X. X.; Rocchi, P.; Qu, F. Q.; Zheng, S. Q.; Liang, Z. C.; Gleave, M.; Iovanna, J.; Peng, L. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. Chem. Med. Chem. 2009, 4 (8), 1302-1310.
44. Torchilin, V. P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9 (2), E128-E147.
45. Carlson, C. B.; Mowery, P.; Owen, R. M.; Dykhuizen, E. C.; Kiessling, L. L. Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol. 2007, 2 (2), 119-127.
46. Lu, Y.; Low, P. S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 2002, 54 (5), 675-693.
47. Bai, S.; Thomas, C.; Rawat, A.; Ahsan, F. Recent progress in dendrimer-based nanocarriers. Crit. Rev. Ther. Drug Carrier Syst. 2006, 23 (6), 437-495.
48. De Smedt, S. C.; Demeester, J.; Hennink, W. E. Cationic polymer based gene delivery systems. Pharm. Res. 2000, 17 (2), 113-126.
49. Schiffelers, R. M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P. Y.; Scaria, P. V.; Woodle, M. C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32 (19), e149.
50. Seymour, L. W.; Ferry, D. R.; Anderson, D.; Hesslewood, S.; Julyan, P. J.; Poyner, R.; Doran, J.; Young, A. M.; Burtles, S.; Kerr, D. J. Hepatic drug targeting: phase I evaluation of polymerbound doxorubicin. J. Clin. Oncol. 2002, 20 (6), 1668-1676.
51. Heath, J. R.; Davis, M. E. Nanotechnology and cancer. Annu. Rev. Med. 2008, 59, 251-265.
52. Das, M.; Mohanty, C.; Sahoo, S. K. Ligand-based targeted therapy for cancer tissue. Expert Opin. Drug Deliv. 2009, 6 (3), 285-304.
53. Drummond, D. C.; Hong, K.; Park, J. W.; Benz, C. C.; Kirpotin, D. B. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam. Horm. 2000, 60, 285-332.
54. Sahoo, S. K.; Labhasetwar, V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm. 2005, 2 (5), 373-383.
55. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66 (13), 6732-6740.
56. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2 (1), 48-58.
57. Reiter, Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv. Cancer Res. 2001, 81, 93-124.
58. Pestourie, C.; Tavitian, B.; Duconge, F. Aptamers against extracellular targets for in vivo applications. Biochimie 2005, 87 (9-10), 921-930.
59. Ireson, C. R.; Kelland, L. R. Discovery and development of anticancer aptamers. Mol. Cancer Ther. 2006, 5 (12), 2957-2962.
60. De Mejia, E. G.; Prisecaru, V. I. Lectins as bioactive plant proteins: a potential in cancer treatment. Crit. Rev. Food Sci. Nutr. 2005, 45 (6), 425-445.
61. Hossen, M. N.; Kajimoto, K.; Akita, H.; Hyodo, M.; Ishitsuka, T.; Harashima, H. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. J. Control Release 2010, 147 (2), 261-268.
62. Stella, B.; Arpicco, S.; Peracchia, M. T.; Desmaele, D.; Hoebeke, J.; Renoir, M.; D'Angelo, J.; Cattel, L.; Couvreur, P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 2000, 89 (11), 1452-1464.
63. Kummer, U.; Thierfelder, S.; Mysliwietz, J. Antigen density on target cells determines the immunosuppressive potential of rat IgG2b monoclonal antibodies. Eur. J. Immunol. 1990, 20 (1), 107-112.
64. Yousaf, N.; Howard, J. C.; Williams, B. D. Targeting behavior of rat monoclonal IgG antibodies in vivo: role of antibody isotype, specificity and the target cell antigen density. Eur. J. Immunol. 1991, 21 (4), 943-950.
65. Park, J. W.; Hong, K.; Kirpotin, D. B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U. B.; Marks, J. D.; Moore, D.; Papahadjopoulos, D.; Benz, C. C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8 (4), 1172-1181.
66. Eniola, A. O.; Hammer, D. A. Artificial polymeric cells for targeted drug delivery. J. Control Release 2003, 87 (1/3), 15-22.
67. Sinha, R.; Kim, G. J.; Nie, S.; Shin, D. M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 2006, 5 (8), 1909-1917.
68. Adams, G. P.; Schier, R.; McCall, A. M.; Simmons, H. H.; Horak, E. M.; Alpaugh, R. K.; Marks, J. D.; Weiner, L. M. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001, 61 (12), 4750-4755.
69. Juweid, M.; Neumann, R.; Paik, C.; Perez-Bacete, M. J.; Sato, J.; van Osdol, W.; Weinstein, J. N. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992, 52 (19), 5144-5153.
70. Lopes de Menezes, D. E.; Pilarski, L. M.; Allen, T. M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998, 58 (15), 3320-3330.
71. Gruner, B. A.; Weitman, S. D. The folate receptor as a potential therapeutic anticancer target. Invest. New Drugs 1998, 16 (3), 205-219.
72. Zhao, D.; Zhao, X.; Zu, Y.; Li, J.; Zhang, Y.; Jiang, R.; Zhang, Z. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int. J. Nanomedicine 2010, 5, 669-677.
73. Choi, C. H.; Alabi, C. A.; Webster, P.; Davis, M. E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (3), 1235-1240.
74. Beck, A.; Wurch, T.; Bailly, C.; Corvaia, N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010, 10 (5), 345-352.
75. Muller, D.; Kohler, G.; Ohlinger, R. Staging procedures in primary breast cancer. Anticancer Res. 2008, 28 (4C), 2397-2400.
76. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 2001, 1 (2), 118-29.
77. Fischgrabe, J.; Wulfing, P. Targeted therapies in breast cancer: established drugs and recent developments. Curr. Clin. Pharmacol. 2008, 3 (2), 85-98.
78. Wang, X.; Yang, L.; Chen, Z. G.; Shin, D. M. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin. 2008, 58 (2), 97-110.
79. Clynes, R. A.; Towers, T. L.; Presta, L. G.; Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6 (4), 443-446.
80. Vives, E.; Schmidt, J.; Pelegrin, A. Cell-penetrating and celltargeting peptides in drug delivery. Biochim. Biophys. Acta 2008, 1786 (2), 126-138.
81. Balestrieri, M. L.; Napoli, C. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur. J. Cancer 2007, 43 (8), 1242-1250.
82. Futaki, S.; Masui, Y.; Nakase, I.; Sugiura, Y.; Nakamura, T.; Kogure, K.; Harashima, H. Unique features of a pH-sensitive fusogenic peptide that improves the transfection efficiency of cationic liposomes. J. Gene Med. 2005, 7 (11), 1450-1458.
83. Zhang, Z.; Cao, W.; Jin, H.; Lovell, J. F.; Yang, M.; Ding, L.; Chen, J.; Corbin, I.; Luo, Q.; Zheng, G. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem. Int. Ed. Engl. 2009, 48 (48), 9171-9175.
84. Misra, R.; Sahoo, S. K. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur. J. Pharm. Sci. 2010, 39 (1-3), 152-163.
85. Bartlett, D. W.; Su, H.; Hildebrandt, I. J.; Weber, W. A.; Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (39), 15549-15554.
86. Perrault, S. D.; Walkey, C.; Jennings, T.; Fischer, H. C.; Chan, W. C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009, 9 (5), 1909-1915.
87. Heldin, C. H.; Rubin, K.; Pietras, K.; Ostman, A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4 (10), 806-813.
88. Agensys, Clinical Research and Development. http://clinicaltrials.gov/2010.
89. Grimm, D.; Bauer, J.; Pietsch, J.; Infanger, M.; Eucker, J.; Eilles, C.; Schoenberger, J. Diagnostic and therapeutic use of membrane proteins in cancer cells. Curr. Med. Chem. 2010.
90. Mesters, J. R.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B. S.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006, 25 (6), 1375-1384.
91. Murphy, G. P.; Elgamal, A. A.; Su, S. L.; Bostwick, D. G.; Holmes, E. H. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998, 83 (11), 2259-2269.
92. Kawakami, M.; Nakayama, J. Enhanced expression of prostatespecific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997, 57 (12), 2321-234.
93. Wang, X.; Yin, L.; Rao, P.; Stein, R.; Harsch, K. M.; Lee, Z.; Heston, W. D. Targeted treatment of prostate cancer. J. Cell Biochem. 2007, 102 (3), 571-579.
94. Slovin, S. F. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin. Ther. Targets 2005, 9 (3), 561-570.
95. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997, 3 (1), 81-85.
96. Schulke, N.; Varlamova, O. A.; Donovan, G. P.; Ma, D.; Gardner, J. P.; Morrissey, D. M.; Arrigale, R. R.; Zhan, C.; Chodera, A. J.; Surowitz, K. G.; Maddon, P. J.; Heston, W. D.; Olson, W. C. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (22), 12590-12595.
97. Ghosh, A.; Heston, W. D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell Biochem. 2004, 91 (3), 528-539.
98. Kinoshita, Y.; Kuratsukuri, K.; Landas, S.; Imaida, K.; Rovito, P. M., Jr.; Wang, C. Y.; Haas, G. P. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J. Surg. 2006, 30 (4), 628-636.
99. Liu, H.; Rajasekaran, A. K.; Moy, P.; Xia, Y.; Kim, S.; Navarro, V.; Rahmati, R.; Bander, N. H. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998, 58 (18), 4055-4060.
100. Buhler, P.; Wolf, P.; Elsasser-Beile, U. Targeting the prostatespecific membrane antigen for prostate cancer therapy. Immunotherapy 2009, 1 (3), 471-481.
101. Elsasser-Beile, U.; Buhler, P.; Wolf, P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr. Drug Targets 2009, 10 (2), 118-125.
102. Elsasser-Beile, U.; Wolf, P.; Gierschner, D.; Buhler, P.; Schultze- Seemann, W.; Wetterauer, U. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006, 66 (13), 1359-1370.
103. Liu, J.; Kopeckova, P.; Buhler, P.; Wolf, P.; Pan, H.; Bauer, H.; Elsasser-Beile, U.; Kopecek, J. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol. Pharm. 2009, 6 (3), 959-970.
104. Wolf, P.; Gierschner, D.; Buhler, P.; Wetterauer, U.; Elsasser-Beile, U. A recombinant PSMA-specific single-chain immunotoxinhas potent and selective toxicity against prostate cancer cells. Cancer Immunol. Immunother. 2006, 55 (11), 1367-1373.
105. Zhang, A. X.; Murelli, R. P.; Barinka, C.; Michel, J.; Cocleaza, A.; Jorgensen, W. L.; Lubkowski, J.; Spiegel, D. A. A remote arenebinding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J. Am. Chem. Soc. 2010, 132 (36), 12711-12716.
106. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Pro.c Natl. Acad. Sci. U. S. A. 2008, 105 (45), 17356-17361.
107. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (16), 6315-6320.
108. Macedo, M. F.; de Sousa, M. Transferrin and the transferring receptor: of magic bullets and other concerns. Inflamm. Allergy Drug Targets 2008, 7 (1), 41-52.
109. Daniels, T. R.; Delgado, T.; Rodriguez, J. A.; Helguera, G.; Penichet, M. L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 2006, 121 (2), 144-158.
110. Keer, H. N.; Kozlowski, J. M.; Tsai, Y. C.; Lee, C.; McEwan, R. N.; Grayhack, J. T. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J. Urol. 1990, 143 (2), 381-385.
111. Inoue, T.; Cavanaugh, P. G.; Steck, P. A.; Brunner, N.; Nicolson, G. L. Differences in transferrin response and numbers of transferring receptors in rat and human mammary carcinoma lines of different metastatic potentials. J. Cell Physiol. 1993, 156 (1), 212-217.
112. Li, H.; Sun, H.; Qian, Z. M. The role of the transferrin-transferrinreceptor system in drug delivery and targeting. Trends Pharmacol. Sci. 2002, 23 (5), 206-209.
113. Qian, Z. M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54 (4), 561-587.
114. Wang, J.; Tian, S.; Petros, R. A.; Napier, M. E.; Desimone, J. M. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. Chem. Soc. 2010, 132 (32), 11306-11313.
115. Gomme, P. T.; McCann, K. B.; Bertolini, J. Transferrin: structure, function and potential therapeutic actions. Drug Discov. Today 2005, 10 (4), 267-273.
116. Prost, A. C.; Menegaux, F.; Langlois, P.; Vidal, J. M.; Koulibaly, M.; Jost, J. L.; Duron, J. J.; Chigot, J. P.; Vayre, P.; Aurengo, A.; Legrand, J. C.; Rosselin, G.; Gespach, C. Differential transferring receptor density in human colorectal cancer: A potential probe for diagnosis and therapy. Int. J. Oncol. 1998, 13 (4), 871-875.
117. Daniels, T. R.; Delgado, T.; Helguera, G.; Penichet, M. L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 2006, 121 (2), 159-176.
118. Zheng, Y.; Yu, B.; Weecharangsan, W.; Piao, L.; Darby, M.; Mao, Y.; Koynova, R.; Yang, X.; Li, H.; Xu, S.; Lee, L. J.; Sugimoto, Y.; Brueggemeier, R. W.; Lee, R. J. Transferrin-conjugated lipidcoated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int. J. Pharm. 2010, 390 (2), 234-241.
119. Weaver, M.; Laske, D. W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. 2003, 65 (1), 3-13.
120. Davis, M. E.; Zuckerman, J. E.; Choi, C. H.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464 (7291), 1067-1070.
121. Hubert, R. S.; Vivanco, I.; Chen, E.; Rastegar, S.; Leong, K.; Mitchell, S. C.; Madraswala, R.; Zhou, Y.; Kuo, J.; Raitano, A. B.; Jakobovits, A.; Saffran, D. C.; Afar, D. E. STEAP: a prostatespecific cell-surface antigen highly expressed in human prostate tumors. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (25), 14523-14528.
122. Rodeberg, D. A.; Nuss, R. A.; Elsawa, S. F.; Celis, E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin. Cancer Res. 2005, 11 (12), 4545-4552.
123. Challita-Eid, P. M.; Morrison, K.; Etessami, S.; An, Z.; Morrison, K. J.; Perez-Villar, J. J.; Raitano, A. B.; Jia, X. C.; Gudas, J. M.; Kanner, S. B.; Jakobovits, A. Monoclonal antibodies to sixtransmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res. 2007, 67 (12), 5798-5805.
124. Azumi, M.; Kobayashi, H.; Aoki, N.; Sato, K.; Kimura, S.; Kakizaki, H.; Tateno, M. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer. J. Urol. 2010, 183 (5), 2036-2044.
125. Garcia-Hernandez Mde, L.; Gray, A.; Hubby, B.; Kast, W. M. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 2007, 67 (3), 1344-1351.
126. Wang, J.; Weng, J.; Cai, Y.; Penland, R.; Liu, M.; Ittmann, M. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alphamethylacyl-CoA racemase. Prostate 2006, 66 (8), 847-857.
127. Weng, J.; Wang, J.; Cai, Y.; Stafford, L. J.; Mitchell, D.; Ittmann, M.; Liu, M. Increased expression of prostate-specific G-proteincoupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int. J. Cancer 2005, 113 (5), 811-818.
128. Xu, L. L.; Stackhouse, B. G.; Florence, K.; Zhang, W.; Shanmugam, N.; Sesterhenn, I. A.; Zou, Z.; Srikantan, V.; Augustus, M.; Roschke, V.; Carter, K.; McLeod, D. G.; Moul, J. W.; Soppett, D.; Srivastava, S. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res. 2000, 60 (23), 6568-6572.
129. Xu, L. L.; Sun, C.; Petrovics, G.; Makarem, M.; Furusato, B.; Zhang, W.; Sesterhenn, I. A.; McLeod, D. G.; Sun, L.; Moul, J. W.; Srivastava, S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis. 2006, 9 (1), 56-61.
130. Tamura, T.; Chiba, J. Production of antibodies against multipass membrane proteins expressed in human tumor cells using dendritic cell immunization. J. Biomed. Biotechnol. 2009, 2009, 673098.
131. Neuhaus, E. M.; Zhang, W.; Gelis, L.; Deng, Y.; Noldus, J.; Hatt, H. Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J. Biol. Chem. 2009, 284 (24), 16218-25.
132. Markwalder, R.; Reubi, J. C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999, 59 (5), 1152-1159.
133. Schroeder, R. P.; de Visser, M.; van Weerden, W. M.; de Ridder, C. M.; Reneman, S.; Melis, M.; Breeman, W. A.; Krenning, E. P.; de Jong, M. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Int. J. Cancer 2010, 126 (12), 2826-2834.
134. Gugger, M.; Reubi, J. C. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol. 1999, 155 (6), 2067-2076.
135. Toi-Scott, M.; Jones, C. L.; Kane, M. A., Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer 1996, 15 (3), 341-354.
136. Cornelio, D. B.; Roesler, R.; Schwartsmann, G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann. Oncol. 2007, 18 (9), 1457-1466.
137. Stangelberger, A.; Schally, A. V.; Varga, J. L.; Zarandi, M.; Cai, R. Z.; Baker, B.; Hammann, B. D.; Armatis, P.; Kanashiro, C. A. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. Eur. J. Cancer 2005, 41 (17), 2735-2744.
138. Stangelberger, A.; Schally, A. V.; Varga, J. L.; Zarandi, M.; Szepeshazi, K.; Armatis, P.; Halmos, G. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin. Cancer Res. 2005, 11 (1), 49-57.
139. Bajo, A. M.; Schally, A. V.; Groot, K.; Szepeshazi, K. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br. J. Cancer 2004, 90 (1), 245-252.
140. Pujatti, P. B.; Santos, J. S.; Couto, R. M.; Melero, L. T.; Suzuki, M. F.; Soares, C. R.; Grallert, S. R.; Mengatti, J.; De Araujo, E. B. Novel series of 177Lu-labeled bombesin derivatives with amino acidic spacers for selective targeting of human PC-3 prostate tumor cells. Q. J. Nucl. Med. Mol. Imaging 2010, 55 (3), 310-323.
141. Chanda, N.; Kattumuri, V.; Shukla, R.; Zambre, A.; Katti, K.; Upendran, A.; Kulkarni, R. R.; Kan, P.; Fent, G. M.; Casteel, S. W.; Smith, C. J.; Boote, E.; Robertson, J. D.; Cutler, C.; Lever, J. R.; Katti, K. V.; Kannan, R. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (19), 8760-8765.
142. Nock, B. A.; Nikolopoulou, A.; Galanis, A.; Cordopatis, P.; Waser, B.; Reubi, J. C.; Maina, T. Potent bombesin-like peptides for GRPreceptor targeting of tumors with 99mTc: a preclinical study. J. Med. Chem. 2005, 48 (1), 100-110.
143. De Laurentiis, M.; Arpino, G.; Massarelli, E.; Ruggiero, A.; Carlomagno, C.; Ciardiello, F.; Tortora, G.; D'Agostino, D.; Caputo, F.; Cancello, G.; Montagna, E.; Malorni, L.; Zinno, L.; Lauria, R.; Bianco, A. R.; De Placido, S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin. Cancer Res. 2005, 11 (13), 4741-4748.
144. Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26 (45), 6469-6487.
145. Horiguchi, S.; Hishima, T.; Hayashi, Y.; Shiozawa, Y.; Horiguchi, K.; Kuroi, K.; Toi, M.; Funata, N.; Eishi, Y. HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. J. Med. Dent. Sci. 2010, 57 (2), 155-163.
146. Jorgensen, J. T. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010, 78 (1), 26-33.
147. Safran, H.; Steinhoff, M.; Mangray, S.; Rathore, R.; King, T. C.; Chai, L.; Berzein, K.; Moore, T.; Iannitti, D.; Reiss, P.; Pasquariello, T.; Akerman, P.; Quirk, D.; Mass, R.; Goldstein, L.; Tantravahi, U. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. 2001, 24 (5), 496-499.
148. Berger, R.; Lin, D. I.; Nieto, M.; Sicinska, E.; Garraway, L. A.; Adams, H.; Signoretti, S.; Hahn, W. C.; Loda, M. Androgendependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006, 66 (11), 5723-5728.
149. Craft, N.; Shostak, Y.; Carey, M.; Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 1999, 5 (3), 280-285.
150. Di Lorenzo, G.; Autorino, R.; De Laurentiis, M.; Cindolo, L.; D'Armiento, M.; Bianco, A. R.; De Placido, S. HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 2004, 90 (2), 163-170.
151. Montemurro, F.; Redana, S.; Viale, G.; Sanna, G.; Donadio, M.; Valabrega, G.; del Curto, B.; Bottini, A.; Botti, G.; dei Tos, A. P.; Jacomuzzi, M. E.; Di Bonito, M.; Danese, S.; Clavarezza, M.; Kulka, J.; Di Palma, S.; Durando, A.; Sapino, A.; Aglietta, M. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumabbased therapy in the pre-lapatinib era. Clin. Breast Cancer 2008, 8 (5), 436-442.
152. Peethambaram, P. P.; Melisko, M. E.; Rinn, K. J.; Alberts, S. R.; Provost, N. M.; Jones, L. A.; Sims, R. B.; Lin, L. R.; Frohlich, M. W.; Park, J. W. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin. Cancer Res. 2009, 15 (18), 5937-5944.
153. Baxevanis, C. N.; Voutsas, I. F.; Gritzapis, A. D.; Perez, S. A.; Papamichail, M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010, 2 (2), 213-226.
154. Lekka, E.; Gritzapis, A. D.; Perez, S. A.; Tsavaris, N.; Missitzis, I.; Mamalaki, A.; Papamichail, M.; Baxevanis, C. N. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy. Cancer Immunol. Immunother. 2010, 59 (5), 715-727.
155. Perez, S. A.; Kallinteris, N. L.; Bisias, S.; Tzonis, P. K.; Georgakopoulou, K.; Varla-Leftherioti, M.; Papamichail, M.; Thanos, A.; von Hofe, E.; Baxevanis, C. N. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin. Cancer Res. 2010, 16 (13), 3495-3506.
156. Lara, P. N., Jr.; Chee, K. G.; Longmate, J.; Ruel, C.; Meyers, F. J.; Gray, C. R.; Edwards, R. G.; Gumerlock, P. H.; Twardowski, P.; Doroshow, J. H.; Gandara, D. R. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004, 100 (10), 2125-2131.
157. Kim, P. H.; Sohn, J. H.; Choi, J. W.; Jung, Y.; Kim, S. W.; Haam, S.; Yun, C. O. Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials 2011, 32 (9), 2314-2326.
158. Richter, K.; Haslbeck, M.; Buchner, J., The heat shock response: life on the verge of death. Mol. Cell 2010, 40 (2), 253-266.
159. Calderwood, S. K.; Khaleque, M. A.; Sawyer, D. B.; Ciocca, D. R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci. 2006, 31 (3), 164-172.
160. Byun, J.; Logothetis, C. J.; Gorlov, I. P. Housekeeping genes in prostate tumorigenesis. Int. J. Cancer 2009, 125 (11), 2603-2608.
161. Tan, S. S.; Ahmad, I.; Bennett, H. L.; Singh, L.; Nixon, C.; Seywright, M.; Barnetson, R. J.; Edwards, J.; Leung, H. Y. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J. Pathol. 2011, 223 (1), 81-87.
162. Rocchi, P.; Beraldi, E.; Ettinger, S.; Fazli, L.; Vessella, R. L.; Nelson, C.; Gleave, M. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 2005, 65 (23), 11083-11093.
163. Rocchi, P.; Jugpal, P.; So, A.; Sinneman, S.; Ettinger, S.; Fazli, L.; Nelson, C.; Gleave, M. Small interference RNA targeting heatshock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int. 2006, 98 (5), 1082-1089.
164. Rocchi, P.; So, A.; Kojima, S.; Signaevsky, M.; Beraldi, E.; Fazli, L.; Hurtado-Coll, A.; Yamanaka, K.; Gleave, M. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 2004, 64 (18), 6595-6602.
165. Banerjee, S.; Lin, C. F.; Skinner, K. A.; Schiffhauer, L. M.; Peacock, J.; Hicks, D. G.; Redmond, E. M.; Morrow, D.; Huston, A.; Shayne, M.; Langstein, H. N.; Miller-Graziano, C. L.; Strickland, J.; O'Donoghue, L.; De, A. K. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res. 2011, 71 (2), 318-327.
166. Ferrarini, M.; Heltai, S.; Zocchi, M. R.; Rugarli, C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992, 51 (4), 613-619.
167. Gehrmann, M.; Liebisch, G.; Schmitz, G.; Anderson, R.; Steinem, C.; De Maio, A.; Pockley, G.; Multhoff, G. Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS One 2008, 3 (4), e1925.
168. Multhoff, G.; Botzler, C.; Jennen, L.; Schmidt, J.; Ellwart, J.; Issels, R. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J. Immunol. 1997, 158 (9), 4341-4350.
169. Multhoff, G.; Botzler, C.; Wiesnet, M.; Muller, E.; Meier, T.; Wilmanns, W.; Issels, R. D. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int. J. Cancer 1995, 61 (2), 272-279.
170. Ni, M.; Zhang, Y.; Lee, A. S. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem. J. 2011, 434 (2), 181-188.
171. Graner, M. W.; Raynes, D. A.; Bigner, D. D.; Guerriero, V. Heat shock protein 70-binding protein 1 is highly expressed in highgrade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds br ain tumor cell surfaces. Cancer Sci. 2009, 100 (10), 1870-1879.
172. Bausero, M. A.; Page, D. T.; Osinaga, E.; Asea, A. Surface expression of Hsp25 and Hsp72 differentially regulates tumor growth and metastasis. Tumour Biol. 2004, 25 (5/6), 243-251.
173. Misra, U. K.; Payne, S.; Pizzo, S. V. Ligation of prostate cancer cell surface GRP78 activates a pro-proliferative and anti-apoptotic feedback loop: A role for secreted PSA. J. Biol. Chem. 2011, 286 (2) 1248-1259.
174. Liu, X.; Yan, Z.; Huang, L.; Guo, M.; Zhang, Z.; Guo, C. Cell surface heat shock protein 90 modulates prostate cancer cell adhesion and invasion through the integrin-beta1/focal adhesion kinase/c-Src signaling pathway. Oncol. Rep. 2011, 25 (5), 1343-1351.
175. Arap, M. A.; Lahdenranta, J.; Mintz, P. J.; Hajitou, A.; Sarkis, A. S.; Arap, W.; Pasqualini, R. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 2004, 6 (3), 275-284.
176. Davidson, D. J.; Haskell, C.; Majest, S.; Kherzai, A.; Egan, D. A.; Walter, K. A.; Schneider, A.; Gubbins, E. F.; Solomon, L.; Chen, Z.; Lesniewski, R.; Henkin, J. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface expressed glucose-regulated protein 78. Cancer Res. 2005, 65 (11), 4663-4672.
177. Piselli, P.; Vendetti, S.; Poccia, F.; Cicconi, R.; Mattei, M.; Bolognesi, A.; Stirpe, F.; Colizzi, V. In vitro and in vivo efficacy of heat shock protein specific immunotoxins on human tumor cells. J. Biol. Regul. Homeost. Agents 1995, 9 (2), 55-62.
178. Stangl, S.; Gehrmann, M.; Riegger, J.; Kuhs, K.; Riederer, I.; Sievert, W.; Hube, K.; Mocikat, R.; Dressel, R.; Kremmer, E.; Pockley, A. G.; Friedrich, L.; Vigh, L.; Skerra, A.; Multhoff, G. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (2), 733-738.
179. Saul, J. M.; Annapragada, A. V.; Bellamkonda, R. V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control Release 2006, 114 (3), 277-287.